Clinical Trials SuccessThe Phase III VELA program concluded its recruitment phase with 800 patients approximately 40% faster than the industry average, indicating strong momentum.
Market OpportunityUpdated market research and claims data analyses build on evidence suggesting HS could represent a $10-15bn market opportunity by 2035.
Product DifferentiationInitial data from the Phase 2 LEDA study of SLK in PPP suggest potential differentiation vs. competing agents and the opportunity to tap into an attractive market with no approved therapies in the US or Europe.